Niraj Shah came to NPCS with a clear sense of direction but a lot of open questions. Based in Nairobi, he wanted to build something meaningful in East Africa's healthcare sector — a large-scale manufacturing venture that would serve real institutional demand and hold up financially over the long term. What he needed was an expert who could tell him whether the opportunity was as real as it looked, and exactly what it would take to execute it.

After evaluating options across healthcare consumables, chemical manufacturing, agro-processing, and packaging, NPCS recommended IV fluid manufacturing as the strongest fit.

The reasoning was grounded. Kenya — and the broader East African region — imports a substantial portion of its intravenous fluid supply from Asia and Europe. Hospitals, clinics, and surgical centers consume IV fluids daily without exception. It's not a discretionary purchase that fluctuates with consumer sentiment. And while the global IV fluids market was valued at around USD 13.8 billion in 2025, projected to reach USD 28.2 billion by 2033 at a CAGR of roughly 9.6%, the regional story was the more compelling one: a significant local demand gap, limited domestic manufacturing, and neighboring markets in Tanzania, Uganda, Ethiopia, and Rwanda with similar supply dependencies.

For an investor willing to meet the technical and regulatory bar, the import substitution angle alone made a strong case.

NPCS worked through the project in structured phases. The market assessment covered Kenya's hospital infrastructure, bed capacity growth, current IV fluid import volumes, and competitive supply dynamics. From there, we moved into the technical evaluation — and IV fluid manufacturing doesn't leave much room for shortcuts. This is sterile pharmaceutical production. It requires cleanroom facilities, aseptic filling lines, autoclave sterilization, Water for Injection systems built to WFI standards, and full compliance with both Kenya's Pharmacy and Poisons Board requirements and WHO GMP guidelines.

We laid out the complete manufacturing process: multi-stage water purification through reverse osmosis, electrodeionization, and distillation; sterile formulation in SS316L jacketed mixing vessels; 0.22 micron membrane filtration; automated aseptic filling into PP or PVC bags; terminal sterilization by autoclave at 121°C; endotoxin and sterility testing; and automated labeling and secondary packaging before distribution to healthcare facilities.

The financial modeling covered the full investment picture. Plant setup costs were estimated in the range of USD 2.5 million to USD 4.5 million depending on capacity and automation level, with working capital requirements of USD 500,000 to USD 800,000 for the first six to twelve months of operations. Projected gross margins ran between 35% and 50%, reflecting the premium pricing that pharmaceutical-grade consumables typically command. IRR projections came in at 18% to 25% or above, with a payback period of four to six years on conservative demand assumptions.

We also built out a phased implementation roadmap — from site selection and regulatory consultation through detailed engineering, civil construction, cleanroom build-out, machinery installation, GMP certification, trial production batches, and commercial launch. The full timeline to production ran approximately sixteen months, with export market entry into neighboring countries identified as a medium-term growth pathway.

Niraj Shah reviewed the feasibility study and moved forward with project implementation planning. That decision reflected exactly what this kind of work is meant to produce: not excitement based on a general sense that an opportunity exists, but confidence grounded in data, process clarity, and a realistic financial model.